Role of STAT3 pathway in genitourinary tumors-Reference-Cited by-同舟云学术

Role of STAT3 pathway in genitourinary tumors

Published:2015-11 Issue:3 Volume:1 Page:
ISSN:2056-5623
Container-title:Future Science OA
language:en
Short-container-title:Future Science OA

Author:

Santoni Matteo¹,Conti Alessandro²,Piva Francesco³,Massari Francesco⁴,Ciccarese Chiara⁴,Burattini Luciano¹,Cheng Liang⁵,Lopez-Beltran Antonio⁶,Scarpelli Marina⁷,Santini Daniele⁸,Tortora Giampaolo⁴,Cascinu Stefano¹,Montironi Rodolfo⁷

Affiliation:

1. Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi, Ancona, Italy

2. Department of Specialistic Clinical & Odontostomatological Sciences, Section of Urology, Polytechnic University of Marche, Ancona 60126, Italy

3. Department of Clinical Sciences, Polytechnic University of the Marche Region, Piazza Roma 22, 60121 Ancona, Italy

4. Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy

5. Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA

6. Department of Surgery, Cordoba University Medical School, Cordoba, Spain

7. Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy

8. Medical Oncology Department, University Campus Bio-Medico, Rome, Italy

Abstract

The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial–mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF. STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role of STAT3 in genitourinary tumors, thus describing its potential for future therapeutic strategies. Regulation of the protein STAT3 is often dysfunctional in genitourinary tumors, including prostate, bladder and kidney cancer. STAT3 is involved in the generation of these tumors and has an effect in their response to treatments. In this review, we describe its role in genitourinary tumors and discuss its potential for use in future therapies.

Publisher

Future Science Ltd

Subject

Biotechnology

Link

https://www.future-science.com/doi/pdf/10.4155/fso.15.13

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer;BMC Complementary Medicine and Therapies;2024-02-01

2. Immuno-Modulatory Effects of Korean Mistletoe in MDA-MB-231 Breast Cancer Cells and THP-1 Macrophages;Scientia Pharmaceutica;2023-10-18

3. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies;Environmental Research;2023-09

4. Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT;Cancer Cell International;2023-06-24

5. Immunobiochemical profile of clear cell renal cell carcinoma (ccRCC): A preliminary study;General physiology and biophysics;2023